Metabolic Changes, Cognitive Improvements in Multiple Sclerosis Observed Through Intermittent Calorie Restriction
Feb 27, 2023 – Marco Meglio Compared with those on an unrestricted diet, patients with MS on intermittent calorie restriction…
Gauging MS Disease Activity Through Octave’s MSDA Test
Feb 24, 2023 Taylor Gonyou, DO The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on…
Stuart Schlossman
BTK Inhibitor Evobrutinib Displays Superior Efficacy Compared With Anti-CD20 Treatment for MS
Feb 25, 2023 – Isabella Ciccone, MPH A preclinical assessment of evobrutinib showed it demonstrated superior efficacy in targeting compartmentalized…
Stuart Schlossman
Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis
Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical…
Stuart Schlossman
Omega-3 fatty acid reduced disease severity in MS mouse model
Study findings could lead to new solutions in managing MS symptoms by Marisa Wexler, MS | February 16, 2023 Treatment…
Stuart Schlossman
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, MD1; Heinz Wiendl, MD2; Karsten Roth, PhD3; et al Hendrik Wessels, PhD3; Josef Höfler, PhD4; Cyrill Hornuss, MD5; Bernd Liedert, PhD5; Krzysztof Selmaj, MD, PhD6 Author Affiliations Article Information JAMA Neurol. Published online January 23, 2023. doi:10.1001/jamaneurol.2022.5007 Key Points Question Does proposed biosimilar…
Stuart Schlossman
Almost No Cases Found of Celiac Disease and MS in New Analysis / Investigating links between celiac disease and MS
Prevalence of gluten-caused disease in MS patients is close to zero by Patricia Inacio, PhD | January 18, 2023 This…
Stuart Schlossman
A discovery at the Oklahoma Medical Research Foundation is shedding new light on a particularly devastating form of multiple sclerosis: PPMS
January 10, 2023 OMRF scientists say their finding could lead to a treatment breakthrough for primary-progressive MS, which may…
Stuart Schlossman
FDA OKs Phase 3 Trial of Masitinib for Progressive Forms of MS
By Lindsey Shapiro, PhD on 01/03/2023 The U.S. Food and Drug Administration (FDA) has cleared AB Science to initiate a Phase 3…
Stuart Schlossman
Antidepressant Bupropion Found to Ease Sexual Dysfunction in MS
Dec 2022 Daily treatment with an oral antidepressant called bupropion — marketed as Wellbutrin and Zyban, among others — significantly improved some…
Stuart Schlossman
